7 ALS Headlines


1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA

herantis als

Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on its application for orphan drug designation for CDNF as a potential treatment for amyotrophic lateral sclerosis (ALS).

A positive opinion is the first step toward orphan drug designation which, in Europe, is issued by the European Commission.

Read more about it: http://bit.ly/1UCyxD2

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This